The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small-cell lung cancer and a poor performance status.
 
Joao Victor Machado Alessi
No Relationships to Disclose
 
Biagio Ricciuti
No Relationships to Disclose
 
Elizabeth Jimenez Aguilar
No Relationships to Disclose
 
Fangxin Hong
Consulting or Advisory Role - Merck Sharp & Dohme
 
Zihan Wei
No Relationships to Disclose
 
Mizuki Nishino
Honoraria - Roche Pharma AG
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo
Research Funding - AstraZeneca (Inst); Daiichi Sankyo (Inst); Merck (Inst); Toshiba (Inst)
 
Andrew J. Plodkowski
No Relationships to Disclose
 
Peter Sawan
No Relationships to Disclose
 
Jia Luo
No Relationships to Disclose
 
Hira Rizvi
No Relationships to Disclose
 
Brett W. Carter
No Relationships to Disclose
 
John Heymach
Stock and Other Ownership Interests - Bio-Tree; Cardinal Spine
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; EMD Serono; Genentech/Roche; GlaxoSmithKline; Guardant Health; Hengrui Pharmaceutical; Lilly; Sanofi/Aventis; Spectrum Pharmaceuticals; Syntha Pharmaceutical; Takeda
Research Funding - AstraZeneca (Inst); Bayer; GlaxoSmithKline; Spectrum Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Licensing agreement between Spectrum and MD Anderson (including myself) regarding intellectual property for treatment of EGFR and HER2 exon 20 mutations
 
Mehmet Altan
Consulting or Advisory Role - GlaxoSmithKline; Shattuck Labs
Research Funding - Adaptimmune (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Jounce Therapeutics (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst)
 
Matthew David Hellmann
Stock and Other Ownership Interests - Immunai; Shattuck Labs
Honoraria - AstraZeneca; Bristol-Myers Squibb
Consulting or Advisory Role - AstraZeneca/MedImmune; Blueprint Medicines; Bristol-Myers Squibb; Genentech; Immunai; Merck; Mirati Therapeutics; Nektar; Shattuck Labs; Syndax
Research Funding - Bristol-Myers Squibb (Inst)
Patents, Royalties, Other Intellectual Property - A patent has been filed by Memorial Sloan Kettering (PCT/US2015/062208) for the use of tumor mutation burden for prediction of immunotherapy efficacy, and which is licensed to Personal Genome Diagnostics. (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb
 
Mark M. Awad
Consulting or Advisory Role - Abbvie; Achilles Therapeutics; ARIAD; AstraZeneca/MedImmune; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Foundation Medicine; Genentech; Gritstone Bio; Hengrui Therapeutics; Maverick Therapeutics; Merck; Nektar; Neon Therapeutics; Novartis; Pfizer; Syndax
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lilly (Inst)